MyBlueDotsBioSkryb Genomics Launches ResolveSEQ MRD: A Next-Generation Measurable Residual Disease (MRD) Discovery Solution MyBlueDots6 months ago01 mins DURHAM, N.C.–(BUSINESS WIRE)–BioSkryb launches ResolveSEQ MRD, an innovative service offering designed to empower further classification and characterization of MRD cells. Post navigation Previous: Instem Introduces Cloud-Hosted Non-GLP Pathology Module for ProvantisNext: RefleXion Launches Pivotal Study to Expand SCINTIX Therapy and Announces Broader Medicare Reimbursement
Why we need to take concussion and chronic traumatic encephalopathy more seriously MyBlueDots4 days ago 0
Foreign medical residents fill critical positions at US hospitals, but are running into visa issues MyBlueDots5 days ago 0